Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
74°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
226.63
+0.23 (+0.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
45
46
Next >
Omicron Surge
December 09, 2021
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
Where Biogen Stands With Analysts
December 06, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) withi...
Via
Benzinga
Biogen Leads From the Top With Disability Inclusion
December 03, 2021
SOURCE: Biogen
Via
3BL Media
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
December 08, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Early Clinical Data Suggest This New Lotion Could Offer Best-In-Class Eczema Treatment and Infection Prevention, According to Hoth Therapeutics
December 07, 2021
Image Provided By Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
From Pause to Pride: A Mother's Journey
December 01, 2021
SOURCE: Biogen
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
Where Biogen Stands With Analysts
November 19, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
Should You Blame Biogen for Medicare Part B Premium Hikes?
December 03, 2021
Yes -- at least partially.
Via
The Motley Fool
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
December 01, 2021
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone...
Via
Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
December 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
December 01, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
November 30, 2021
Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Youth Neurology Program: Building a More Diverse Neurology Workforce
November 30, 2021
SOURCE: Biogen
Via
3BL Media
Exposures
COVID-19
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
November 28, 2021
The Swiss pharma needs to get its drug approved first.
Via
The Motley Fool
Exposures
Product Safety
Wanda Castro-Borrero: Carrying on Legacy of Care
November 23, 2021
SOURCE: Biogen
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
2 Moonshot Biotechs with 10x Potential
November 22, 2021
This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same.
Via
InvestorPlace
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...
Via
Benzinga
Exposures
Product Safety
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
European Regulator Votes Down Biogen's Alzheimer's Drug
November 17, 2021
Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen Inc (NASDAQ: BIIB) received "a negative trend vote...
Via
Benzinga
Biogen Stock Skids After Alzheimer's Drug Aduhelm Faces A Setback In Europe
November 17, 2021
The committee voted against recommending Aduhelm approval.
Via
Investor's Business Daily
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
November 17, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ:
Via
Benzinga
Could Eli Lilly Leapfrog Biogen in This Market?
November 17, 2021
Biogen is benefiting from a first-mover advantage, but the race is far from over.
Via
The Motley Fool
Europe OKs Biogen's Vumerity For Multiple Sclerosis
November 16, 2021
The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS...
Via
Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
November 16, 2021
Warren Buffet's Berkshire Hathaway added more than 13 million shares.
Via
Investor's Business Daily
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
November 16, 2021
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.